265 related articles for article (PubMed ID: 11295629)
1. Design considerations for efficient prostate cancer chemoprevention trials.
Lee JJ; Lieberman R; Sloan JA; Piantadosi S; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):205-12. PubMed ID: 11295629
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
Lieberman R
Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
[TBL] [Abstract][Full Text] [Related]
3. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
[TBL] [Abstract][Full Text] [Related]
4. SELECT: the selenium and vitamin E cancer prevention trial.
Klein EA; Thompson IM; Lippman SM; Goodman PJ; Albanes D; Taylor PR; Coltman C
Urol Oncol; 2003; 21(1):59-65. PubMed ID: 12684129
[TBL] [Abstract][Full Text] [Related]
5. Randomized, controlled chemoprevention trials in populations at very high risk for prostate cancer: Elevated prostate-specific antigen and high-grade prostatic intraepithelial neoplasia.
Clark LC; Marshall JR
Urology; 2001 Apr; 57(4 Suppl 1):185-7. PubMed ID: 11295623
[TBL] [Abstract][Full Text] [Related]
6. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
7. Designing a randomized phase I/II prostate cancer chemoprevention trial using 1alpha-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D3.
Packianathan S; Mehta RG; Mehta RR; Hall WH; Boerner PS; Beckett LA; Vijayakumar S
Cancer J; 2004; 10(6):357-67. PubMed ID: 15701267
[TBL] [Abstract][Full Text] [Related]
8. Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia.
Marshall JR; Sakr W; Wood D; Berry D; Tangen C; Parker F; Thompson I; Lippman SM; Lieberman R; Alberts D; Jarrard D; Coltman C; Greenwald P; Minasian L; Crawford ED
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1479-84. PubMed ID: 16896036
[TBL] [Abstract][Full Text] [Related]
9. Challenges and opportunities to the design and implementation of chemoprevention trials for prostate cancer.
Thompson IM; Basler JA; Leach R; Troyer D; Klein E; Brawley O
Urol Oncol; 2003; 21(1):73-8. PubMed ID: 12684131
[TBL] [Abstract][Full Text] [Related]
10. Opportunities and challenges in incorporating ancillary studies into a cancer prevention randomized clinical trial.
Goodman PJ; Tangen CM; Darke AK; Arnold KB; Hartline J; Yee M; Anderson K; Caban-Holt A; Christen WG; Cassano PA; Lance P; Klein EA; Crowley JJ; Minasian LM; Meyskens FL
Trials; 2016 Aug; 17():400. PubMed ID: 27519183
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer chemoprevention agent development: the National Cancer Institute, Division of Cancer Prevention portfolio.
Parnes HL; House MG; Kagan J; Kausal DJ; Lieberman R
J Urol; 2004 Feb; 171(2 Pt 2):S68-74; discussion S75. PubMed ID: 14713758
[TBL] [Abstract][Full Text] [Related]
12. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer chemoprevention.
Sandhu GS; Nepple KG; Tanagho YS; Andriole GL
Semin Oncol; 2013 Jun; 40(3):276-85. PubMed ID: 23806493
[TBL] [Abstract][Full Text] [Related]
14. Statistical design issues and other practical considerations for conducting phase III prostate cancer prevention trials.
Tangen CM; Goodman PJ; Crowley JJ; Thompson IM
J Urol; 2004 Feb; 171(2 Pt 2):S64-7. PubMed ID: 14713757
[TBL] [Abstract][Full Text] [Related]
15. Validation of surrogate endpoint biomarkers in prostate cancer chemoprevention trials.
Trock BJ
Urology; 2001 Apr; 57(4 Suppl 1):241-7. PubMed ID: 11295636
[TBL] [Abstract][Full Text] [Related]
16. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"?
Gontero P; Marra G; Soria F; Oderda M; Zitella A; Baratta F; Chiorino G; Gregnanin I; Daniele L; Cattel L; Frea B; Brusa P
Prostate; 2015 Aug; 75(11):1177-86. PubMed ID: 25893930
[TBL] [Abstract][Full Text] [Related]
17. The future of prostate cancer prevention.
Brawley OW; Barnes S; Parnes H
Ann N Y Acad Sci; 2001 Dec; 952():145-52. PubMed ID: 11795434
[TBL] [Abstract][Full Text] [Related]
18. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
Bostwick DG; Aquilina JW
J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of prostate cancer: current status and future directions.
Lieberman R
Cancer Metastasis Rev; 2002; 21(3-4):297-309. PubMed ID: 12549768
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer prevention: strategies for agent development.
Parnes HL; House MG; Tangrea JA
Curr Opin Oncol; 2013 May; 25(3):242-51. PubMed ID: 23518594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]